CAR M cells have also been observed to exert "bystander effects" by secreting pro-inflammatory cytokines that activate other immune cells, such as T cells, to target tumor cells [410], reduce the efficacy of anti-VEGF antibody therapy, and undermining its therapeutic potential [411, 412] (Fig. 2). This evidence concerns the gene VEGFA and neoplasm.